Creative Planning Has $509,000 Stake in Omnicell, Inc. (NASDAQ:OMCL)

Creative Planning increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 23.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,667 shares of the company’s stock after buying an additional 2,188 shares during the period. Creative Planning’s holdings in Omnicell were worth $509,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Federated Hermes Inc. increased its holdings in shares of Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares during the last quarter. Pacer Advisors Inc. increased its holdings in shares of Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after purchasing an additional 508,789 shares during the last quarter. Champlain Investment Partners LLC increased its holdings in shares of Omnicell by 16.0% in the first quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock valued at $51,246,000 after purchasing an additional 241,235 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Omnicell by 61.3% in the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after purchasing an additional 228,093 shares during the last quarter. Finally, Liontrust Investment Partners LLP acquired a new position in shares of Omnicell in the second quarter valued at $4,066,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Trading Up 2.7 %

OMCL stock opened at $49.80 on Wednesday. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74. The company’s 50-day simple moving average is $43.49 and its 200 day simple moving average is $35.75. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.95 and a current ratio of 1.05. The company has a market capitalization of $2.29 billion, a PE ratio of -127.69, a price-to-earnings-growth ratio of 53.65 and a beta of 0.81.

Wall Street Analysts Forecast Growth

Several research firms have commented on OMCL. Wells Fargo & Company upped their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Barclays upped their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Bank of America restated a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Finally, Benchmark restated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $50.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.